CClinicalTrials.gg
TerminatedNCT04533373Updated Apr 11, 2025

Sensory Restoration After DIEP Flap Neurotization

An interventional study of DIEP Flap Neurotization in Breast Cancer, Breast Reconstruction and Sensory Restoration, sponsored by Johns Hopkins University. Terminated at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Treatment

Why this study was terminated
IRB expired
Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Common goals of breast reconstruction include obtaining satisfactory breast symmetry, softness, and appropriate size and shape. Advances in surgical techniques have prompted a new goal: achieving breast sensation after reconstructive surgery. This desire has led the surgical community to investigate operative techniques for achieving this goal. However, few studies have examined the effectiveness of breast sensory restoration.

Sensory nerves are nerves responsible for sensation from skin. When a sensory nerve is cut, sensation is lost to the area supplied by the nerve. In the case of Breast reconstruction this involves the nerves supplying the skin overlying breast(s). 'Neurotization' refers to regeneration of the nerve after it has been cut. This means that the cut nerve is being repaired in order to restore its function. In Neurotization this repair is carried out using a new "source". In this case, the investigators want to restore function of the nerves that supply the skin overlying the breast(s).

The investigators will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new "source") that is being transferred and attaching it to a nerve in the chest wall.

The Avance® Nerve graft is a nerve graft material that has been produced by Axogen, Inc. The graft is made by processing donated human nerves. This graft is used during neurotization to bridge the gap and join the nerve from the abdominal tissue to the nerve in the chest wall. The use of the graft helps the body to attach these 2 nerves and improves nerve repair.

When neurotization is done without the nerve graft there is a possibility that the surgeon may require extra nerve material to join the 2 nerves. Traditionally, in this case the surgeon would have to obtain a separate donor nerve from another part of the patient's body. This technique carries the risk of complications to part of the body that the separate donor nerve was obtained from - loss of sensation, infection or neuroma formation (an abnormal growth of nerve tissue that can cause pain, burning or tingling sensation, numbness). The Avance nerve graft avoids the need for the additional donor nerve and the possible complications associated with it.

The Avance® Nerve Graft is currently being used in some women during breast reconstruction surgery, however the effectiveness of this procedure in improving the restoration of sensation has not been proven.

Women undergoing reconstruction of one breast and at the same time using the women's own tissue as part of standard clinical care, may join.

02

Conditions studied

  • Breast Cancer
  • Breast Reconstruction
  • Sensory Restoration
03

In context

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.

Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. All patients presenting to Johns Hopkins who have had or will have mastectomy (therapeutic or prophylactic) and are planning to undergo unilateral mastectomy followed by breast reconstruction with autologous deep inferior epigastric perforator flap (DIEP) will be included.

    These patients will then be randomized in either of two treatment modalities:

    • Treatment Modality 1: Breast reconstruction with DIEP flap and neurotization.
    • Treatment Modality 2: Breast reconstruction with DIEP flap but without neurotization.
  2. 18 years of age and older
  3. The patient is aware of the nature of her malignancy if a malignancy has been diagnosed; understands the study purpose, requirements, and risks; and is able and willing to sign an informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Autologous reconstruction where the flap is buried.
  2. Exclusion criteria will encompass any patient with: diabetic neuropathy, thyroid disorders, collagen vascular disease, alcoholism, pernicious anemia, or any other severe underlying peripheral neuropathy including chemotherapy-induced neuropathy or neuropathy induced by other medications.
  3. Pregnant or lactating women will be excluded from this study.
  4. Women with recurrent breast cancer will be excluded.
  5. Women with previous reconstructive procedures or who have previously undergone lumpectomy with radiation will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    Neurotized Patients

    Neurotization will be performed at the time of reconstruction.

    Procedure: DIEP Flap Neurotization

  • No intervention
    Non-Neurotized Patients

    No Neurotization will be performed at the time of reconstruction.

Interventions

  • ProcedureDIEP Flap Neurotization

    We will be performing breast reconstruction using tissue from the patient's abdomen and transferring it to the chest wall to repair the mastectomy defect. Sensory function is restored by using the nerve that supplies the skin of this abdominal tissue (i.e the new "source") that is being transferred and attaching it to a nerve in the chest wall.

06

What researchers measure

Primary outcomes

  1. 12-month Breast sensation as assessed by the AcroValTM device

    Breast sensation, measured in cutaneous thresholds using the AcroValTM device.

    Time frame: 12-months after DIEP Flap neurotization

Secondary outcomes

  1. Breast sensation at 6 months as assessed by the AcroValTM device

    Breast sensation, measured in cutaneous thresholds using the AcroValTM device.

    Time frame: 6 months after DIEP flap breast reconstruction

  2. Breast sensation at 18 months as assessed by the AcroValTM device

    Breast sensation, measured in cutaneous thresholds using the AcroValTM device.

    Time frame: 18 months after DIEP flap breast reconstruction

  3. Breast sensation at 24 months as assessed by the AcroValTM device

    Breast sensation, measured in cutaneous thresholds using the AcroValTM device.

    Time frame: 24 months after DIEP flap breast reconstruction

  4. Breast-specific health-related quality of life using the Breast-Q®

    The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

    Time frame: 6 months after DIEP flap breast reconstruction

  5. Breast-specific health-related quality of life using the Breast-Q®

    The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

    Time frame: 12 months after DIEP flap breast reconstruction

  6. Breast-specific health-related quality of life using the Breast-Q®

    The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

    Time frame: 18 months after DIEP flap breast reconstruction

  7. Breast-specific health-related quality of life using the Breast-Q®

    The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

    Time frame: 24 months after DIEP flap breast reconstruction

  8. General health-related quality of life using the SF-12

    The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.

    Time frame: 6 months after DIEP flap breast reconstruction

  9. General health-related quality of life using the SF-12

    The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.

    Time frame: 12 months after DIEP flap breast reconstruction

  10. General health-related quality of life using the SF-12

    The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.

    Time frame: 18 months after DIEP flap breast reconstruction

  11. General health-related quality of life using the SF-12

    The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.

    Time frame: 24 months after DIEP flap breast reconstruction

  12. Change in breast sensation as assessed by the AcroValTM device

    Change in breast sensation from baseline, measured in cutaneous thresholds using the AcroValTM device.

    Time frame: Baseline, 6, 12, 18 and 24 months after DIEP flap breast reconstruction

  13. Change in breast-specific health-related quality of life using the Breast-Q®

    The Breast-Q® is a validated patient reported outcomes questionnaire used to assess Breast specific patient satisfaction and Health-related quality of life. The Breast-Q is comprised of 2 domains - i) Satisfaction domains and ii) Well-being domains, which are further divided into sub-domains. We will be using 3 satisfaction sub-domains: i) Satisfaction with breasts ii) Satisfaction with Nipple iii) Satisfaction with outcome and 3 well-being sub-domains: i) Psychosocial well-being ii) Sexual well-being and iii) Physical well-being Each sub-domain will be scored on a scale of 0-100, where higher scores will indicate higher satisfaction.

    Time frame: Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction

  14. Change in general health-related quality of life using the SF-12

    The SF-12 is a multipurpose short form (SF) survey with 12 questions, all selected from the SF-36 Health Survey. It has 2 components - i) Physical Health Composite score and ii) Mental Health Composite score. Each composite score is marked on a scale of 0-100, where a higher score indicates higher quality of life.

    Time frame: Baseline, 6, 12, 18, and 24 months after DIEP flap breast reconstruction

07

Study locations

1 site
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04533373
Lead sponsor
Johns Hopkins University
Collaborators
Axogen Corporation
Responsible party
Sponsor
First posted
Aug 31, 2020
Start date
Dec 1, 2020
Primary completion
Sep 11, 2024
Completion
Sep 11, 2024
Last update
Apr 11, 2025

Study contacts

Gedge D Rosson, MD
principal investigator · Johns Hopkins University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion